The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs : a meta-analysis
The notion that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes upon acquisition of coronavirus disease 2019 (COVID-19) should be discredited with a review of the real-life evidence. We aimed to perform a meta-analysis to summarize the risk of mortality with the preadmission/pre-diagnosis use of NSAIDs in patients with COVID-19. A systematic literature search was performed to identify eligible studies in electronic databases. The outcome of interest was the development of a fatal course of COVID-19. Adjusted hazard ratio or odds ratio/relative risk and the corresponding 95% confidence interval from each study were pooled using a random-effects model to produce pooled hazard ratio and pooled odds ratio, along with 95% confidence interval. The meta-analysis of 3 studies with a total of 2414 patients with COVID-19 revealed no difference in the hazard for the development of a fatal course of COVID-19 between NSAID users and non-NSAID users (pooled hazard ratio = 0.86; 95% confidence interval 0.49-1.51). Therefore, NSAIDs should not be avoided in patients who are appropriately indicated during the COVID-19 pandemic.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Inflammopharmacology - 29(2021), 3 vom: 21. Juni, Seite 641-644 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Inflammatory Agents, Non-Steroidal |
---|
Anmerkungen: |
Date Completed 07.07.2021 Date Revised 07.07.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10787-021-00810-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324360193 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324360193 | ||
003 | DE-627 | ||
005 | 20231225190146.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10787-021-00810-1 |2 doi | |
028 | 5 | 2 | |a pubmed24n1081.xml |
035 | |a (DE-627)NLM324360193 | ||
035 | |a (NLM)33881684 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
245 | 1 | 4 | |a The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs |b a meta-analysis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.07.2021 | ||
500 | |a Date Revised 07.07.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The notion that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes upon acquisition of coronavirus disease 2019 (COVID-19) should be discredited with a review of the real-life evidence. We aimed to perform a meta-analysis to summarize the risk of mortality with the preadmission/pre-diagnosis use of NSAIDs in patients with COVID-19. A systematic literature search was performed to identify eligible studies in electronic databases. The outcome of interest was the development of a fatal course of COVID-19. Adjusted hazard ratio or odds ratio/relative risk and the corresponding 95% confidence interval from each study were pooled using a random-effects model to produce pooled hazard ratio and pooled odds ratio, along with 95% confidence interval. The meta-analysis of 3 studies with a total of 2414 patients with COVID-19 revealed no difference in the hazard for the development of a fatal course of COVID-19 between NSAID users and non-NSAID users (pooled hazard ratio = 0.86; 95% confidence interval 0.49-1.51). Therefore, NSAIDs should not be avoided in patients who are appropriately indicated during the COVID-19 pandemic | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Review | |
650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 29(2021), 3 vom: 21. Juni, Seite 641-644 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2021 |g number:3 |g day:21 |g month:06 |g pages:641-644 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-021-00810-1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2021 |e 3 |b 21 |c 06 |h 641-644 |